158 related articles for article (PubMed ID: 12393712)
1. Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells.
Pisano C; Kollar P; Gianní M; Kalac Y; Giordano V; Ferrara FF; Tancredi R; Devoto A; Rinaldi A; Rambaldi A; Penco S; Marzi M; Moretti G; Vesci L; Tinti O; Carminati P; Terao M; Garattini E
Blood; 2002 Nov; 100(10):3719-30. PubMed ID: 12393712
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways.
Parrella E; Gianni' M; Cecconi V; Nigro E; Barzago MM; Rambaldi A; Rochette-Egly C; Terao M; Garattini E
J Biol Chem; 2004 Oct; 279(40):42026-40. PubMed ID: 15292163
[TBL] [Abstract][Full Text] [Related]
3. Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro.
Shiohara M; Dawson MI; Hobbs PD; Sawai N; Higuchi T; Koike K; Komiyama A; Koeffler HP
Blood; 1999 Mar; 93(6):2057-66. PubMed ID: 10068679
[TBL] [Abstract][Full Text] [Related]
4. Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro.
Kizaki M; Dawson MI; Heyman R; Elster E; Morosetti R; Pakkala S; Chen DL; Ueno H; Chao W; Morikawa M; Ikeda Y; Heber D; Pfahl M; Koeffler HP
Blood; 1996 Mar; 87(5):1977-84. PubMed ID: 8634447
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha.
Gianni' M; Kalaç Y; Ponzanelli I; Rambaldi A; Terao M; Garattini E
Blood; 2001 May; 97(10):3234-43. PubMed ID: 11342454
[TBL] [Abstract][Full Text] [Related]
6. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
[TBL] [Abstract][Full Text] [Related]
7. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites.
Idres N; Benoît G; Flexor MA; Lanotte M; Chabot GG
Cancer Res; 2001 Jan; 61(2):700-5. PubMed ID: 11212271
[TBL] [Abstract][Full Text] [Related]
8. Induction of retinoic acid receptor-alpha by granulocyte macrophage colony-stimulating factor in human myeloid leukemia cell lines.
Shimizu T; Takeda K
Cancer Res; 2000 Aug; 60(16):4544-9. PubMed ID: 10969805
[TBL] [Abstract][Full Text] [Related]
9. RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells.
Gianni M; Fratelli M; Bolis M; Kurosaki M; Zanetti A; Paroni G; Rambaldi A; Borleri G; Rochette-Egly C; Terao M; Garattini E
Oncotarget; 2017 Jun; 8(23):37041-37060. PubMed ID: 27419624
[TBL] [Abstract][Full Text] [Related]
10. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia.
Niitsu N; Higashihara M; Honma Y
Exp Hematol; 2002 Nov; 30(11):1273-82. PubMed ID: 12423680
[TBL] [Abstract][Full Text] [Related]
11. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways.
Glasow A; Prodromou N; Xu K; von Lindern M; Zelent A
Blood; 2005 Jan; 105(1):341-9. PubMed ID: 15339853
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death.
Pendino F; Dudognon C; Delhommeau F; Sahraoui T; Flexor M; Bennaceur-Griscelli A; Lanotte M; Ségal-Bendirdjian E
Oncogene; 2003 Dec; 22(57):9142-50. PubMed ID: 14668795
[TBL] [Abstract][Full Text] [Related]
13. Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia.
Wang H; Zheng X; Behm FG; Ratnam M
Blood; 2000 Nov; 96(10):3529-36. PubMed ID: 11071651
[TBL] [Abstract][Full Text] [Related]
14. A functionally active RARalpha nuclear receptor is expressed in retinoic acid non responsive early myeloblastic cell lines.
Grande A; Montanari M; Manfredini R; Tagliafico E; Zanocco-Marani T; Trevisan F; Ligabue G; Siena M; Ferrari S; Ferrari S
Cell Death Differ; 2001 Jan; 8(1):70-82. PubMed ID: 11313705
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells.
Ikezoe T; Tanosaki S; Krug U; Liu B; Cohen P; Taguchi H; Koeffler HP
Blood; 2004 Jul; 104(1):237-42. PubMed ID: 15026318
[TBL] [Abstract][Full Text] [Related]
16. Pharicin B stabilizes retinoic acid receptor-α and presents synergistic differentiation induction with ATRA in myeloid leukemic cells.
Gu ZM; Wu YL; Zhou MY; Liu CX; Xu HZ; Yan H; Zhao Y; Huang Y; Sun HD; Chen GQ
Blood; 2010 Dec; 116(24):5289-97. PubMed ID: 20739655
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
Ying M; Zhou X; Zhong L; Lin N; Jing H; Luo P; Yang X; Song H; Yang B; He Q
Mol Cancer Ther; 2013 Feb; 12(2):195-206. PubMed ID: 23243061
[TBL] [Abstract][Full Text] [Related]
18. p38αMAPK interacts with and inhibits RARα: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells.
Gianni M; Peviani M; Bruck N; Rambaldi A; Borleri G; Terao M; Kurosaki M; Paroni G; Rochette-Egly C; Garattini E
Leukemia; 2012 Aug; 26(8):1850-61. PubMed ID: 22354283
[TBL] [Abstract][Full Text] [Related]
19. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation.
Zhao Q; Tao J; Zhu Q; Jia PM; Dou AX; Li X; Cheng F; Waxman S; Chen GQ; Chen SJ; Lanotte M; Chen Z; Tong JH
Leukemia; 2004 Feb; 18(2):285-92. PubMed ID: 14628075
[TBL] [Abstract][Full Text] [Related]
20. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
